Decellularized tissue-engineered heart valves: as novel off-the-whelf homologous valve replacements
Dijkman, P.E.; Driessen - Mol, A.; Hoerstrup, S.; Baaijens, F.P.T.

Published: 01/01/2011

Document Version
Accepted manuscript including changes made at the peer-review stage

Please check the document version of this publication:
• A submitted manuscript is the author's version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal?

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Introduction

Biological valve prostheses are created from decellularized xeno- or homografts, which are either associated with the risk of immunogenic reactions and disease transmission (xenografts) or low availability (homografts). Tissue-engineered heart valves (TEHV), based on largely available biodegradable synthetic scaffolds, have no risk for disease transmission and have shown promising results in-vivo [1,2]. However, substantial regurgitation (fig. 1A) is observed due to cell-mediated retraction of the leaflets (fig. 2A&B).

Aim: We propose to decellularize TEHV in order to create off-the-shelf homologous valve replacements without cell-mediated retraction or graft related limitations.

Methods & Materials

TEHV (n=11), based on rapid degrading scaffolds, were engineered from ovine vascular-derived cells. After 4 weeks in-vitro culturing, TEHV (n=8) were decellularized. Either directly (n=6) or after 18 months storage (n=2), valves were analyzed for cell removal and preservation of ECM by histology and biochemical assays. Additionally, mechanical properties and in-vitro functionality were tested and compared to their cell-populated counterparts (n=3).

Results

After decellularization, in-vitro valve functionality was improved (fig. 3) due to reduced retraction of the leaflets (fig. 4A&B). Histology demonstrated the removal of all cells and F-actin after decellularization (fig. 5A vs E & 5B vs F) without altering the collagen structure (fig. 5C&D vs 5G&H), which was confirmed by biochemical analysis (fig. 6A). GAG content decreased by decellularization. Although leaflet stiffness increased, the tissue strength was not affected by decellularization (fig. 6B). Storage of the decellularized TEHV for 18 months did not affect the biochemical contents or biomechanical properties (fig. 6A&B, respectively).

Conclusions

Decellularization of TEHV is feasible with efficient cell removal and preservation of collagen structure and tissue strength. Reduced retraction improved valve functionality. No changes upon storage enables off-the-shelf availability. We hereby provide largely available homologous valve replacements, which can serve as alternative starter matrices to homo- and xenografts.

References